Eulav Asset Management Madrigal Pharmaceuticals, Inc. Transaction History
Eulav Asset Management
- $4.25 Billion
- Q2 2025
A detailed history of Eulav Asset Management transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Eulav Asset Management holds 31,000 shares of MDGL stock, worth $13.2 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
31,000
Previous 10,000
210.0%
Holding current value
$13.2 Million
Previous $3.31 Million
183.24%
% of portfolio
0.22%
Previous 0.08%
Shares
4 transactions
Others Institutions Holding MDGL
# of Institutions
355Shares Held
23.2MCall Options Held
738KPut Options Held
473K-
Janus Henderson Group PLC London, X02.19MShares$933 Million0.34% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.09MShares$889 Million32.86% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$849 Million9.27% of portfolio
-
Baker Bros. Advisors LP New York, NY1.98MShares$841 Million6.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.88MShares$799 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $7.28B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...